Skp2与Sp1在膀胱尿路上皮癌中的表达及临床意义

发布时间：2018-05-03 21:41

  本文选题：Skp2蛋白 + Sp1蛋白　； 参考：《延边大学》2017年硕士论文

【摘要】：目的:探讨Skp2与Sp1在膀胱尿路上皮癌不同临床分期、病理分级中的表达及两者在同一膀胱癌组织中的相关性,以及与膀胱癌复发的关系。方法:选取延边大学附属医院2012年1月-2015年12月间手术切除后确诊为膀胱尿路上皮癌的病理标本69例,另选取20例癌旁非肿瘤膀胱粘膜组织供对照实验。所选患者术前均未给予化疗、放疗及免疫治疗。采用免疫组织化学PV-6000法检测69例膀胱癌和20例癌旁非肿瘤膀胱粘膜组织中Skp2及Sp1蛋白表达,分析Skp2及Sp1在膀胱尿路上皮癌的不同临床分期、病理分级中的表达及其临床意义。结果:(1)Skp2在69例膀胱癌组以及20例癌旁非肿瘤膀胱粘膜组中阳性表达率为69.6%和10.0%,具有显著性差异(P0.05)。Skp2在浅表型膀胱癌组和浸润型膀胱癌组中阳性表达率为57.1%和88.9%,具有显著性差异(P0.05)。Skp2在低分级膀胱癌组和高分级膀胱癌组中的阳性表达率为50.0%和80.0%,具有显著性差异(P0.05)。Skp2在复发患者组和未复发患者组中阳性率为85.3%和54.3%,具有显著性差异(P0.05)。(2)Sp1在69例膀胱癌组以及20例癌旁非肿瘤膀胱粘膜组中阳性表达率为81.2%和15.0%,具有显著性差异(P0.05)。Sp1在浅表型膀胱癌组和浸润型膀胱癌组中阳性表达率为71.4%和96.3%,具有显著性差异(P0.05)。Sp1在低分级膀胱癌组和高分级膀胱癌组中的阳性表达率为58.3%和93.3%,具有显著性差异(P0.05)。Sp1在复发患者组和未复发患者组中阳性率为91.2%和71.4%,具有显著性差异(P0.05)。(3)Skp2与Sp1蛋白在同一膀胱癌组织中的表达呈正相关关系(P0.05)。结论:(1)Skp2和Sp1蛋白与膀胱癌的临床分期和病理分级密切相关,提示Skp2和Sp1可能参与了膀胱癌细胞增殖、浸润、转移和复发等过程。(2)Skp2与Sp1在膀胱癌组织中表达呈正相关,推测Sp1可能通过激活Skp2从而促进了膀胱癌的发生和发展,联合检测Skp2与Sp1对评估膀胱癌的预后有一定的参考价值。
[Abstract]:Objective: to investigate the expression of Skp2 and Sp1 in different clinical stages and pathological grades of bladder urothelial carcinoma and their correlation with the recurrence of bladder cancer. Methods: 69 cases of bladder urothelial carcinoma confirmed by surgical resection from January 2012 to December 2015 in affiliated Hospital of Yanbian University were selected and 20 cases of non-cancerous bladder mucosa were selected for control experiment. All the patients were not given chemotherapy, radiotherapy and immunotherapy before operation. The expression of Skp2 and Sp1 in 69 cases of bladder cancer and 20 cases of non-cancerous bladder mucosa were detected by immunohistochemical PV-6000 method. The expression of Skp2 and Sp1 in different clinical stages, pathological grade and clinical significance of bladder urothelial carcinoma were analyzed. Results the positive expression rates of Skp2 in 69 cases of bladder cancer and 20 cases of non-cancerous bladder mucosa were 69.6% and 10.0, respectively. The positive expression rates of Skp2 in superficial bladder carcinoma and invasive bladder cancer were 57.1% and 88.9%, respectively. The positive rate of Skp2 in low grade bladder cancer group and high grade bladder cancer group was 50.0% and 80.0%, respectively. There was significant difference in the positive rate of P0.05N. Skp2 between relapsed patients and non-recurrence patients (85.3% and 54.3%, respectively). In 69 cases of bladder cancer and 20 cases of non-cancerous bladder mucosa adjacent to carcinoma, the positive expression rates were 81.2% and 15.0%, respectively. There was a significant difference in the positive expression rates of P0.05 and Sp1 in superficial bladder cancer and invasive bladder cancer. The positive rates were 71.4% and 96.3%, respectively. The positive expression rates of P0.05U. Sp1 in low grade bladder cancer group and high grade bladder cancer group were 58.3% and 93.3%, respectively. There was a significant difference in the positive rate of P0.05U 路Sp1 between relapsed patients and non-recurrence patients (91.2% and 71.4%, respectively). There was a significant difference between P0.05Skp2 and Sp1 eggs. The expression of white in the same bladder cancer was positively correlated with that of P0.05. Conclusion Skp2 and Sp1 proteins are closely related to the clinical stage and pathological grade of bladder cancer, suggesting that Skp2 and Sp1 may be involved in the process of proliferation, invasion, metastasis and recurrence of bladder cancer cells. The expression of Skp2 and Sp1 in bladder cancer tissues is positively correlated. It is speculated that Sp1 may promote the occurrence and development of bladder cancer by activating Skp2. The combined detection of Skp2 and Sp1 may be useful in evaluating the prognosis of bladder cancer.
【学位授予单位】：延边大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.14

【参考文献】

相关期刊论文 前10条

1 段松;;前列腺癌组织中Skp2的表达及其与前列腺癌术后复发的关系[J];东南国防医药;2016年01期

2 马燕;赵雅淇;严美娟;赵建美;;P27~(kip1)、Jab1、Skp2在非霍奇金淋巴瘤中的表达及意义[J];实用医学杂志;2015年24期

3 杨成成;南克俊;秦思达;;过表达人细胞S期激酶相关蛋白2(Skp2)促进MCF-7乳腺癌细胞生长及S期细胞增加[J];细胞与分子免疫学杂志;2015年10期

4 李胜;梅同华;;抑制skp2基因表达对肺癌移植瘤生长影响的实验研究[J];临床肿瘤学杂志;2015年10期

5 程维刚;李蕾蕾;刘九洲;殷德涛;郭万里;;S期激酶相关蛋白2和细胞周期抑制蛋白p27kip1在乳腺癌组织中的表达及其临床意义[J];中华实验外科杂志;2015年10期

6 刘大闯;梁清;陶陶;黄烨清;许斌;陈恕求;张治国;董洋;韩从辉;陈明;;前列腺癌中Sp1通过PKM2途径促进细胞增殖代谢[J];东南大学学报(医学版);2015年03期

7 赵俊峰;肖耀军;姜耀东;赵善超;杨旭凯;郑少斌;;沉默G250基因对肾癌786-0细胞移植瘤Skp2表达的影响[J];中国老年学杂志;2015年01期

8 赵静;吴娟;杨丽娜;李郁;张芳琳;杨红;;Sp1调控FoxM1在卵巢癌中的表达[J];科学技术与工程;2014年28期

9 张连峰;魏争;韩利坤;张绪文;乔海泉;;RNAi沉默Skp2抑制胃癌细胞SGC7901侵袭作用的实验研究[J];医学综述;2014年12期

10 靳文剑;张q和;陈火国;罗庆丰;;β-Catenin、Skp~2和p~(27)在老年肝细胞癌中的表达及相关性[J];中国老年学杂志;2014年05期

，

本文编号：1840238